Biomarkers for Alzheimer's disease therapeutic trials.

Journal article

The development of disease-modifying treatments for Alzheimer's disease requires innovative trials with large numbers of subjects and long observation periods. The use of blood, cerebrospinal fluid or neuroimaging biomarkers is critical for the demonstration of disease-modifying therapy effects on the brain. Suitable biomarkers are those which reflect the progression of AD related molecular mechanisms and neuropathology, including amyloidogenic processing and aggregation, hyperphosphorylation...

Expand abstract

Authors: Hampel, H; Wilcock, G; Andrieu, S; Aisen, P; Blennow, K

• Publication status: Published
• Journal: Progress in neurobiology
• Volume: 95
• Issue: 4
• Pages: 579-593
• Publication date: 2011-12-01
• DOI: 10.1016/j.pneurobio.2010.11.005
• EISSN: 1873-5118
• ISSN: 0301-0082
• Language: English
• Keywords: Biological Markers; Antipsychotic Agents; Clinical Trials as Topic; Alzheimer Disease; Brain; Humans; Brain Mapping; Oxford Task Force Group